Roth/MKM Reiterates $40 PT on Bio-Path Holdings (BPTH): 'Business Update Includes Developing Prexigebersen For Obesity'
Tweet Send to a Friend
Roth/MKM analyst Philip Shen reiterated a Buy rating and $40.00 price target on Bio-Path Holdings (NASDAQ: BPTH).The analyst comments "BPTH ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
